Search clinical trials for: cetuximab rechallenge

Total 1055 results

Beijing Hospital
Bethune Charitable Foundation

Recruiting

ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC

Metastatic Colorectal Cancer | MSS | RAS Mutation

China
University of Campania "Luigi Vanvitelli"

Recruiting

CAVE-2 GOIM Study: a Clinical Study of the Combination of Avelumab Plus Cetuximab as Rechallenge Strategy

Metastatic Colorectal Cancer

Italy
Fudan University

Not yet recruiting

Cetuximab Re-challenge for Colorectal Cancer Liver Metastasis

Colorectal Cancer | Liver Metastases | Cetuximab
Hadassah Medical Organization
Merck Serono International SA

Terminated

Cetuximab Therapy for Third Line Rechallenge in Metastatic Colorectal Cancer

Cancer of Colon

Israel
Chinese University of Hong Kong

Completed

Cetuximab Rechallenge Study

Metastatic Colorectal Cancer

Hong Kong
Gruppo Oncologico del Nord-Ovest

Unknown

Cetuximab Rechallenge in Irinotecan-pretreated mCRC, KRAS, NRAS and BRAF Wild-type Treated in 1st Line With Anti-EGFR Therapy (CRICKET). (CRICKET)

Metastatic Colorectal Cancer

Italy
GERCOR - Multidisciplinary Oncology Cooperative...

Terminated

Rechallenge of Cetuximab Combined With Irinotecan as Third-line Chemotherapy in Patients With Metastatic Colorectal Cancer - Phase II Study (REGAIN)

Colorectal Cancer Metastatic

France
Fudan University

Recruiting

Exploration of Therapeutic Strategies for NeoRAS Wild-type Metastatic Colorectal Cancer Based on Circulating Tumor DNA

Colorectal Cancer Metastatic

China
Quanta Therapeutics

Not yet recruiting

QTX3046 in Patients With KRAS G12D Mutations

Advanced Solid Tumor
Jinghui Wang

Recruiting

A Prospective, Single-arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Driver Gene-negative Non-small Cell Lung Cancer After Failure of First-line Immunotherapy.

Lung Cancer

China
Melanoma and Skin Cancer Trials Limited

Not yet recruiting

Neoadjuvant PD-1 Inhibitor and EGFR Inhibitor in Locally Advanced Cutaneous Squamous Cell Carcinoma (NEOPECS)

Locally Advanced Cutaneous Squamous Cell Carcinoma
M.D. Anderson Cancer Center

Not yet recruiting

A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations

Metastatic Colorectal Cancer | KRAS G12C Mutations

United States
Vall d'Hebron Institute of Oncology

Not yet recruiting

Combination Therapy for BRAF-V600E Metastatic CRCm (BRAVE)

Metastatic Colorectal Cancer
Peking Union Medical College Hospital

Not yet recruiting

ICI Rechallenge for Advanced NSCLC With Long-Term Response to First-Line ICI

Non-small Cell Lung Cancer

China
Wangxia LV

Recruiting

Trifluridine/Tipiracil Combined With Cetuximab in the Treatment of Third-line and Above RAS/BRAF Wild-type mCRC

Colorectal Cancer Metastatic

China
M.D. Anderson Cancer Center

Not yet recruiting

Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer

Advanced Colorectal Cancer

United States
Saint Petersburg State University, Russia

Recruiting

Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF Therapy

Anaplastic Thyroid Cancer

Russian Federation
M.D. Anderson Cancer Center
Bellicum Pharmaceuticals, Inc.

Not yet recruiting

Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)

Colorectal Cancer | Minimal Residual Disease

United States
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma

Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma

China
Peking University People's Hospital
Peking University Shougang Hospital; Shandong Cancer Hospital and Institute

Recruiting

Weekly Irinotecan Liposomes in Recurrent or Refractory Ewing Sarcoma

Ewing Sarcoma

China
Fulgent Pharma LLC.

Recruiting

FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)

Head and Neck Squamous Cell Carcinoma

United States
Gruppo Oncologico del Nord-Ovest

Recruiting

Holmium-166 TARE in Liver Limited Unresectable Colorectal Cancer Patients (HAITI)

Colorectal Cancer Metastatic

Italy
Hansoh BioMedical R&D Company

Not yet recruiting

ARTEMIS-101: A Study of HS-20093 Combinations in Patients With Advanced Solid Tumors

Advanced Solid Tumor
Qilu Hospital of Shandong University

Recruiting

Chemotherapy With Cetuximab as Conversion Therapy in RAS/BRAF WT Unresectable Liver Metastasis Right-sided Colon Cancer

Colon Cancer

China
Shanghai Henlius Biotech

Not yet recruiting

A Randomized, Single Intravenous Dose, Parallel Phase I Clinical Study to Compare the Pharmacokinetic Characteristics, Safety, and Immunogenicity of HLX05 Vs. Erbitux® (Cetuximab) in Healthy Adult Male Chinese Subjects

EGFR Overexpression
Jiang Feng

Recruiting

Neoadjuvant SBRT in Localized Advanced HNSCC

Head and Neck Squamous Carcinoma

China
Leiden University Medical Center

Not yet recruiting

Durability of Protection After Single Immunisation With GA2 Sporozoites (CoGA-Rechallenge)

Malaria,Falciparum
Xinqiao Hospital of Chongqing
Chongqing Medical University

Not yet recruiting

Thalidomide Enhances Clinical Efficacy of Cetuximab Combined With Standard Chemotherapy for Left Colorectal Cancer

Thalidomide Enhances Clinical Efficacy of Cetuximab Combined With Standard Chemotherapy for Left Colorectal Cancer
Biond Biologics

Not yet recruiting

A Study of BND-35 in Participants With Advanced Solid Tumors

Cancer

Israel
Fate Therapeutics

Recruiting

FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors

Advanced Solid Tumor

United States
Glenn J. Hanna
ImmunityBio, Inc.

Recruiting

PD-L1 t-haNK, N-803 IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC

Head and Neck Cancer | Head and Neck Squamous Cell Carcinoma | Recurrent Head and Neck Squamous Cell Carcinoma | Recurrent Head and Neck Cancer | Metastatic Head and Neck Cancer | Metastatic Head-and-neck Squamous-cell Carcinoma

United States
The First Affiliated Hospital of Zhengzhou University

Recruiting

Adebrelimab Plus Cetuximab and Chemotherapy for Patients With RAS/BRAF Wild-Type Unresectable Liver Metastases Colorectal Cancer

Metastatic Colorectal Cancer

China
Quanta Therapeutics

Recruiting

QTX3034 in Patients With KRAS G12D Mutation

Solid Tumors

United States
City Clinical Oncology Hospital No 1
Atlas Biomed; N.N. Blokhin National Medical Research Center of Oncology; Moscow...

Recruiting

Other Oncogene Mutations for Anti-EGFR Efficacy in Patients With Left-sided RAS-wild Type Metastatic Colorectal Cancer (CRC01)

Colorectal Neoplasms | Chemotherapy Effect | Molecular Sequence Variation

Russian Federation
Shanghai Zhongshan Hospital
CSPC Ouyi Pharmaceutical Co., Ltd.

Recruiting

Dose Escalation and Expansion Clinical Trial of Irinotecan Liposome Combined With Oxaliplatin and 5-FU/LV Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

China
Spanish Cooperative Group for the Treatment of...
Merck, S.L., Spain; Pierre Fabre Ibérica, S.A.

Not yet recruiting

Study to Evaluate the Efficacy and Safety of Cetuximab in Combination With Encorafenib Plus Binimetinib as Induction Treatment in BRAF V600E Mutated MSS Initially Resectable or Potentially Resectable Advanced Colorectal Cancer (CEBBRA)

Colorectal Cancer
Peking University

Recruiting

Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment

Liver Metastasis Colon Cancer | MSS | ctDNA Genotype | Failed From Standard Treatment

China
Shanghai Institute Of Biological Products

Not yet recruiting

Clinical Trial of SIBP-03 in Patients With Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma
MedSIR

Not yet recruiting

Niraparib Rechallenge After Surgery in Ovarian Cancer Patients With Oligometastatic Progression (ANALLISA)

Ovarian Cancer | Oligometastatic Disease | Serous Ovarian Tumor
Incyte Corporation

Recruiting

A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

Solid Tumors

United States, France, Italy, Australia, Spain, Canada, Belgium
Eye & ENT Hospital of Fudan University

Recruiting

Neoadjuvant PD-1 Inhibitor Combined With Cetuximab and Platinum in Resectable Locally Advanced Hypopharyngeal Carcinoma

Locally Advanced Hypopharyngeal Carcinoma

China
Sun Yat-sen University

Recruiting

Crisaborole Ointment for Skin Toxicity Induced by Cetuximab (COSTIC)

Metastatic Colorectal Cancer | Cetuximab | Skin Toxicity

China
Xuekui Liu

Not yet recruiting

Cetuximab+Zimberelimab in Combination With Cisplatin and Nab-paclitaxel in Resctable Head and Neck Squamous Cell Carcinoma (CZCNRHNSCC)

Hend and Neck Squamous Cell Carcinoma Locally Advanced Operable

China
University of Turin, Italy
Azienda Ospedaliera Città della Salute e della Scienza di Torino

Recruiting

Development of a Fluorescent Visualization System for Non-visible Lung Cancer Nodules (RECOGNISE)

Lung Cancer | EGFR | Cetuximab | Video-assisted Thoracic Surgery

Italy
National Cancer Institute (NCI)

Recruiting

Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer

Metastatic Colorectal Adenocarcinoma | Refractory Colorectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8

United States
First Affiliated Hospital of Zhejiang University

Recruiting

Toripalimab in Combined With Cetuximab，Chemotherapy for Conversion Therapy of Locally Nonresectable OCSCC

Squamous Cell Carcinoma of Head and Neck

China
Jonathan Riess
National Cancer Institute (NCI)

Not yet recruiting

Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer

Metastatic Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer AJCC v8 | Recurrent Lung Non-Small Cell Carcinoma

United States
AVEO Pharmaceuticals, Inc.

Recruiting

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma (FIERCE-HN)

Recurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head-and-neck Squamous-cell Carcinoma

United States, Australia, United Kingdom, Canada
Institut für Klinische Krebsforschung IKF GmbH...
PharmaMar

Recruiting

Prospective Study to Evaluate Patient Reported Outcomes (PRO) During Rechallenge With Trabectedin in Sarcoma Patients (PROTraSarc)

Soft Tissue Sarcoma

Germany
Tang-Du Hospital

Not yet recruiting

Treatment of Low Locally Advanced Rectal Cancer With Radiotherapy Removal TNT Plus Neoadjuvant Therapy

Rectal Cancer

3

Subscribe